Name: Zika Virus Specific Diagnostic Epitope Discovery (Video) | JoVE Journal
Uploaded: 2017-12-12T13:00:00.000+00:00
Duration: 11 min 37 s
Description: Discover how to identify Zika virus specific peptides for diagnostic assays using high-density peptide microarrays. This method detects IgM and IgG antibodies to provide clinicians with accurate infection timelines.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

Current support is provided by an SBIR (Small Business Innovation Research) administrative supplement grant from NIDCRR44 DE024456. NIDCR HIV grant that evolved out of NIDCR grant U01 DE017855 for the development of a confirmatory point-of- care diagnostic for HIV. We gratefully acknowledge Silke Weisenburger(PEPperPRINT Heidelberg, Germany) for her technical assistance and kind support. We also thank NYU Langone Medical Center for the LI-COR Odyssey Imaging System.

These data are a part of an ongoing research study conducted at New York University College of Dentistry and were approved by the Institutional Review Board of the New York University School of Medicine, IRB # H10-01894. Clinical samples used in this study were de-identified samples used previously for diagnosis and with permission from the Wadsworth Center of New York State Department of Health, Albany, NY.
1. Installing the ZIKV High-density Peptide Microarray Slide in a specific Incubation Tray
<ol>
	<li>Handle the glass slide by the edges using powder-free gloves. The glass slide dimensions are 75.4 mm by 25.0 mm and 1 mm of thick. Place the slide in the incubation tray with the microarray surface facing up.</li>
	<li>Place the glossy side of the seal facing downwards onto the microarray printed surface. To ensure a good position, overlap the screw holes of the seal and the base plate.</li>
	<li>Place the upper part of the tray onto the seal to create a microarray chamber.</li>
	<li>Secure the slide in the tray by tightening equally the thumbscrews one after another by hand in an alternating pattern starting from the upper left followed by lower right. Place the lid of the incubation tray.</li>
</ol>
2. Background Interaction Detection: Staining the Microarray with Secondary Antibodies
NOTE: Use a pipette to deposit the solutions (standard and blocking buffers, diluted secondary antibodies) in the corner of the microarray chamber.
<ol>
	<li>Incubate the microarray with a standard buffer (1x Phosphate buffered saline (PBS), 0.05% Tween 20, pH 7.4, filtered with a 0.45 &#181;m filter) (total volume of 2,000 &#181;L/microarray) for 15 min at room temperature (RT) on an orbital shaker at 140 rpm.</li>
	<li>Remove the standard buffer by aspirating with a pipette from the corner of the microarray chamber. Fill empty slide holders with blank slides to prevent breaking of the microarray slide.</li>
	<li>Block the microarray with the blocking buffer (total volume of 2,000 &#181;L/microarray) for 60 min at RT on an orbital shaker at 140 rpm.</li>
	<li>Remove the blocking buffer by aspirating with a pipette from the corner of the microarray chamber.</li>
	<li>Incubate the microarray with secondary antibody, anti-human IgM fluorochrome conjugated, diluted 1: 5,000 (total volume of 2,000 &#181;L/microarray) in the staining buffer (10% blocking buffer in standard buffer) for 30 min at RT in the dark on an orbital shaker at 140 rpm.</li>
	<li>Remove the secondary antibody by aspirating with a pipette from the corner of the microarray chamber.</li>
	<li>Wash the microarray 3x, 1 min per wash with standard buffer (total volume of 2,000 &#181;L/microarray at RT on an orbital shaker at 140 rpm. After each wash, remove the standard buffer by aspirating with a pipette from the corner of the microarray chamber.</li>
	<li>Immerse the slide 2x into a freshly prepared dipping buffer (1 mM Tris, pH 7.4), (total volume of 200 mL).</li>
	<li>Dry the microarray carefully, for approximately 1 min, by aspirating excess fluid very carefully from the top to the bottom of the slide without touching the slide surface. Analyze the slide in a microarray scanner reader.</li>
</ol>
3. Exposure of the Microarray to Host Serum
CAUTION: Perform this step under laboratory safety conditions, Biosafety Level 2 (BSL-2) because of the potential infectious nature of the serum specimens. Work within a Class II biological safety cabinet (BSC).
<ol>
	<li>Inactivate serum sample at 56 &#176;C for 30 min and centrifuge at 16,000 rcf for 5 min at 4 &#176;C13. 
	NOTE: Use a pipette to deposit the solutions (staining, standard buffer and diluted serum) in the corner of the microarray chamber.</li>
	<li>Dilute serum sample in staining buffer starting with a 1:1,000 (total volume of 2,000 &#956;L/microarray) dilution. Keep it at 4 &#176;C until use.</li>
	<li>Incubate the microarray with the staining buffer (total volume of 2,000 &#956;L/microarray) for 15 min at RT on an orbital shaker at 140 rpm.</li>
	<li>Remove the staining buffer by aspirating with a pipette from the corner of the microarray chamber.</li>
	<li>Incubate the microarray with the diluted serum sample overnight at 4 &#176;C on an orbital shaker at 140 rpm.</li>
	<li>Remove the diluted serum sample by aspirating with a pipette from the corner of the microarray chamber.</li>
	<li>Wash the microarray 3x, 1 min per wash with standard buffer (total volume of 2,000 &#956;L/microarray at RT on an orbital shaker at 140 rpm. After each wash, remove the standard buffer by aspirating with a pipette from the corner of the microarray chamber.</li>
</ol>
4. Staining with Secondary Antibodies and Labeled Control Antibodies
NOTE: Use a pipette to deposit the solutions (standard buffers, diluted secondary and label antibodies) in the corner of the microarray chamber.
<ol>
	<li>Dilute the secondary antibody in the staining buffer. 
	NOTE: Use anti-human IgM fluorochrome conjugated antibody or anti-human IgG fluorochrome conjugated antibody at a dilution of 1:5,000 (total volume of 2,000 &#181;L/microarray) in staining buffer.</li>
	<li>Mix control label antibody (monoclonal anti-HA fluorochrome conjugated) at a dilution of 1:1,000 (total volume of 2 000 &#181;L/microarray) in staining buffer with secondary antibody previously diluted in staining buffer.</li>
	<li>Incubate with the microarray for 30 min at RT in the dark on an orbital shaker at 140 rpm.</li>
	<li>Remove the mix of diluted secondary and label antibodies by aspirating with a pipette from the corner of the microarray chamber.</li>
	<li>Wash 3x with standard buffer (total volume of 2,000 &#181;L/microarray). Each wash is for 1 min on an orbital shaker at 140 rpm. After each wash, remove the standard buffer by aspirating with a pipette from the corner of the microarray chamber.</li>
</ol>
5. Microarray Scanning
<ol>
	<li>Immerse the slide 2x into freshly prepared dipping buffer (1 mM Tris, pH 7.4) (total volume of 200 mL).</li>
	<li>Dry the microarray carefully, around 1 min, by aspirating very carefully from the top to the bottom of the slide without touching the slide surface.</li>
	<li>Scan the microarray following the instructions of the scanner. Place the slide onto the scanner with the printed surface facing up.</li>
	<li>Create a new project and select the scanning area. Set scanner parameters as: Resolution: 21 &#181;m, Intensity for both 700 and 800 nm channels: 7.0, Scanning quality: medium and Offset: 0.8.</li>
	<li>Acquire and save the scan raw image as a 16-bit grayscale TIFF file format.</li>
</ol>
6. Microarray Analysis Using a Specific Software
<ol>
	<li>Open the raw image (TIFF image). Open the array grid file.</li>
	<li>Align the array grid to the scan image with the computer&#39;s mouse or keyboard arrow keys.</li>
	<li>Select &#34;Quantify Selection&#34; in the specific software, which creates a readout file that contains the signal intensity for each spot, the background value, and the corresponding peptide sequence. 
	NOTE: This output file can also be imported into a spreadsheet program for additional analysis and graphing.</li>
</ol>
7. Microarray Storage
<ol>
	<li>Store the microarray sealed in the dark at 4 &#176;C under oxygen free nitrogen or argon gas.</li>
</ol>

<ol><li>Kelser, E. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Meet+dengue%27s+cousin%5BTitle%5D)+AND+%22Zika.+Microbes+Infect%22%5BJournal%5D)">Meet dengue's cousin.</a> Zika. Microbes Infect. 18 (3), 163-166 (2016).</li>
<li>Musso, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Detection+of+Zika+virus+in+saliva%5BTitle%5D)+AND+%22J+Clin+Virol%22%5BJournal%5D)">Detection of Zika virus in saliva.</a> J Clin Virol. 68, 53-55 (2015).</li>
<li>Siqueira, W. L., et al. <a target="_blank" href="https://www.oralhealthgroup.com/features/oral-clinical-manifestations-patients-infected-zika-virus/">Oral Clinical Manifestations of Patients Infected with Zika Virus.</a> Oral Health. , (2016).</li>
<li>Duarte, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Challenges+of+Zika+Virus+Infection+in+Pregnant+Women%5BTitle%5D)+AND+%22Rev+Bras+Ginecol+Obstet%22%5BJournal%5D)">Challenges of Zika Virus Infection in Pregnant Women.</a> Rev Bras Ginecol Obstet. 38 (6), 263-265 (2016).</li>
<li>Buus, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High-resolution+mapping+of+linear+antibody+epitopes+using+ultrahigh-density+peptide+microarrays%5BTitle%5D)+AND+%22Mol+Cell+Proteomics%22%5BJournal%5D)">High-resolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays.</a> Mol Cell Proteomics. 11 (12), 1790-1800 (2012).</li>
<li>Kouzmitcheva, G. A., Petrenko, V. A., Smith, G. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Identifying+diagnostic+peptides+for+lyme+disease+through+epitope+discovery%5BTitle%5D)+AND+%22Clin+Diagn+Lab+Immunol%22%5BJournal%5D)">Identifying diagnostic peptides for lyme disease through epitope discovery.</a> Clin Diagn Lab Immunol. 8 (1), 150-160 (2001).</li>
<li>Hamby, C. V., Llibre, M., Utpat, S., Wormser, G. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Use+of+Peptide+library+screening+to+detect+a+previously+unknown+linear+diagnostic+epitope%3A+proof+of+principle+by+use+of+lyme+disease+sera%5BTitle%5D)+AND+%22Clin+Diagn+Lab+Immunol%22%5BJournal%5D)">Use of Peptide library screening to detect a previously unknown linear diagnostic epitope: proof of principle by use of lyme disease sera.</a> Clin Diagn Lab Immunol. 12 (7), 801-807 (2005).</li>
<li>t Hoen, P. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Phage+display+screening+without+repetitious+selection+rounds%5BTitle%5D)+AND+%22Anal+Biochem%22%5BJournal%5D)">Phage display screening without repetitious selection rounds.</a> Anal Biochem. 421 (2), 622-631 (2012).</li>
<li>Townend, J. E., Tavassoli, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Traceless+Production+of+Cyclic+Peptide+Libraries+in+E.+coli%5BTitle%5D)+AND+%22ACS+Chem+Biol%22%5BJournal%5D)">Traceless Production of Cyclic Peptide Libraries in E. coli.</a> ACS Chem Biol. 11 (6), 1624-1630 (2016).</li>
<li>Turchetto, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High-throughput+expression+of+animal+venom+toxins+in+Escherichia+coli+to+generate+a+large+library+of+oxidized+disulphide-reticulated+peptides+for+drug+discovery%5BTitle%5D)+AND+%22Microbial+Cell+Factories%22%5BJournal%5D)">High-throughput expression of animal venom toxins in Escherichia coli to generate a large library of oxidized disulphide-reticulated peptides for drug discovery.</a> Microbial Cell Factories. 16 (1), 6(2017).</li>
<li>Carmona, S. J., Sartor, P. A., Leguizamon, M. S., Campetella, O. E., Aguero, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Diagnostic+Peptide+Discovery%3A+Prioritization+of+Pathogen+Diagnostic+Markers+Using+Multiple+Features%5BTitle%5D)+AND+%22Plos+One%22%5BJournal%5D)">Diagnostic Peptide Discovery: Prioritization of Pathogen Diagnostic Markers Using Multiple Features.</a> Plos One. 7 (12), e50748(2012).</li>
<li>Lagatie, O., Van Dorst, B., Stuyver, L. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Identification+of+three+immunodominant+motifs+with+atypical+isotype+profile+scattered+over+the+Onchocerca+volvulus+proteome%5BTitle%5D)+AND+%22PLoS+Negl+Trop+Dis%22%5BJournal%5D)">Identification of three immunodominant motifs with atypical isotype profile scattered over the Onchocerca volvulus proteome.</a> PLoS Negl Trop Dis. 11 (1), e0005330(2017).</li>
<li>Basile, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+and+validation+of+an+ELISA+kit+%28YF+MAC-HD%29+to+detect+IgM+to+yellow+fever+virus%5BTitle%5D)+AND+%22J+Virol+Methods%22%5BJournal%5D)">Development and validation of an ELISA kit (YF MAC-HD) to detect IgM to yellow fever virus.</a> J Virol Methods. 225, 41-48 (2015).</li>
<li>Madden, T. <a target="_blank" href="https://www.ncbi.nlm.nih.gov/books/NBK153387/">The BLAST Sequence Analysis Tool.</a> The NCBI Handbook. , 2nd ed, (2013).</li>
<li>Services, U. S. D. oH. aH. <a target="_blank" href="https://www.cdc.gov/biosafety/publications/bmbl5/">Biosafety in Microbiological and Biomedical Laboratories (BMBL)</a>. , 5th ed, Vol. HHS Publication No. (CDC) 21-1112 (2009).</li>
<li>Pellois, J. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Individually+addressable+parallel+peptide+synthesis+on+microchips%5BTitle%5D)+AND+%22Nat+Biotech%22%5BJournal%5D)">Individually addressable parallel peptide synthesis on microchips.</a> Nat Biotech. 20 (9), 922-926 (2002).</li>
<li>Stafford, P., et al. <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/22261726">Physical Characterization of the "Immunosignaturing Effect".</a> Mol Cell Proteomics. 11 (4), (2012).</li>
<li>Gardner, T. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Functional+screening+for+anti-CMV+biologics+identifies+a+broadly+neutralizing+epitope+of+an+essential+envelope+protein%5BTitle%5D)+AND+%22Nat+Commun%22%5BJournal%5D)">Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein.</a> Nat Commun. 7, (2016).</li>
<li>Nixon, C. E., et al. <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/28468980">Identification of protective B-cell epitopes within the novel malaria vaccine candidate P. falciparum Schizont Egress Antigen-1.</a> Clin Vaccine Immunol. , (2017).</li>
</ol>

The authors have nothing to disclose.

We designed a protocol utilizing a high-density peptide microarray containing the entire Zika virus protein sequence (French Polynesian strain). The microarray was manufactured by printing 3,423 different overlapping linear peptides. Each peptide was 15 amino acids and varied by only one residue from its nearest neighbor in the sequence (i.e., 14 residue overlap). Although shorter overlaps can be printed, epitope mapping is more precise with longer overlaps. Each peptide was printed in duplicate to increase reli...

Zika virus (ZIKV) diagnosis based on clinical symptoms is challenging because it shares vectors, geographic distribution, and symptoms with Dengue and Chikungunya virus infection1. Given the risk for adverse pregnancy outcomes in women infected with ZIKV during pregnancy, it is important to distinguish between the 3 viruses. Although the current molecular diagnostic tests are specific, they are only useful in blood or saliva during the relatively short period of acute infection2,3. Serological assays are essential for diagnosis outside this initial period of infection4.
The development of a ZIKV specific serological assay is challenging for two reasons: first, the Zika antigens that the human immune system responds to are not currently known; and second, conserved flaviviruses amino acid sequences induce antibody cross-reactivity. Our objective was to discover unique ZIKV specific peptides to be used in diagnostics. Different approaches have been developed to screen peptide libraries covering entire proteins including phage, bacterial, and yeast surface display5,6,7,8,9,10. Our strategy was to use a high-density peptide microarray that permits rapid and inexpensive high-throughput serological screenings11,12 and subsequently the identified peptides can be used to improve current serological assays for detection of ZIKV infection.
This protocol enables the discovery of Zika virus specific diagnostic peptides using a high-density peptide microarray (Figure 1). The high-density peptide microarray was produced using the peptide laser printing technology. The entire ZIKV protein sequence consisting of 3,423 amino acid residues based on the French Polynesian strain (GenBank: KJ776791.2), was printed on a standard glass slide in blocks of 15 linear residues with an overlap of 14 amino acid residues in duplicate for a total of 6,846 peptide spots. In addition to the entire Zika protein sequence peptides, the microarray utilizes Influenza hemagglutinin (HA) peptides for internal controls.
A Zika validated positive serum sample obtained from Wadsworth Center (Albany, NY), was used to identify specific Immunoglobulin M (IgM) and Immunoglobulin G (IgG) reactive peptides. After incubating with the sample overnight, the microarray was stained with a secondary fluorochrome conjugated antibody (anti-human IgM or anti-human IgG), and analyzed on a microarray scanner. Quantification of spot intensities and peptide annotation was performed with a specific software provided by the same company that manufactured the microarray.

<table><tbody><tr><td>PEPperCHIP Custom Peptide Microarray</td><td>PEPperPRINT</td><td>PPC.001.001</td><td>Custom peptide micarray: our microarray contains the entire Zika virus protein sequence</td></tr><tr><td>PEPperCHIP incubation tray 3/1</td><td>PEPperPRINT</td><td>PPC.004.001</td><td></td></tr><tr><td>PEPperCHIP Staining Kit (680 nm) (anti-HA, DyLight labeling)</td><td>PEPperPRINT</td><td>PPC.037.002</td><td></td></tr><tr><td>PepSLide Analyzer</td><td>PEPperPRINT</td><td>PSA.004.001</td><td>14-days free License for Windows</td></tr><tr><td>Rockland Blocking buffer</td><td>Rockland</td><td>MB-070</td><td></td></tr><tr><td>anti-human IgM (mu chain) DyLight 800</td><td>Rockland</td><td>609-145-007</td><td></td></tr><tr><td>anti-human IgG Fc DyLight 680</td><td>Thermo Scientific</td><td>SA5-10138</td><td></td></tr><tr><td>LI-COR Odyssey Imaging System</td><td>LI-COR</td><td></td><td></td></tr><tr><td>Orbital shaker device</td><td>IKA</td><td>MTS 2/4 digital microtiter shaker</td><td></td></tr><tr><td>Adobe Illustrator</td><td>Adobe</td><td></td><td></td></tr><tr><td>Deltagraph</td><td>Redrocks</td><td></td><td></td></tr></tbody></table>

zika virus specific diagnostic epitope discovery

Zika Virus Specific Diagnostic Epitope Discovery

High-density peptide microarrays allow screening of more than six thousand peptides on a single standard microscopy slide. This method can be applied for drug discovery, therapeutic target identification, and developing of diagnostics. Here, we present a protocol to discover specific Zika virus (ZIKV) diagnostic peptides using a high-density peptide microarray. A human serum sample validated for ZIKV infection was incubated with a high-density peptide microarray containing the entire ZIKV protein translated into 3,423 unique 15 linear amino acid (aa) residues with a 14-aa residue overlap printed in duplicate. Staining with different secondary antibodies within the same array, we detected peptides that bind to Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies present in serum. These peptides were selected for further validation experiments. In this protocol, we describe the strategy followed to design, process, and analyze a high-density peptide microarray.

The results obtained using the protocol described are shown in Figure 2 and Figure 3. No background interactions were noted when pre-staining the microarray with secondary anti-human IgM (data not shown). Staining with an anti-human IgM conjugate resulted in several areas above background green fluorescence intensities, indicating the binding of these peptides with IgM in the host serum sample (<strong class="xfi...

In this protocol, we describe a technique to discover Zika virus specific diagnostic peptides using a high-density peptide microarray. This protocol can readly be adapted for other emerging infectious diseases.

High-density peptide microarrays allow screening of more than six thousand peptides on a single standard microscopy slide. This method can be applied for ...

zika-virus-specific-diagnostic-epitope-discovery

Research

JoVE Journal

Immunology and Infection

Zika Virus (ZIKV), an emerging pathogen, is linked to fetal developmental abnormalities and microcephaly. The establishment of an effective infectious cell culture system is crucial for studies of ZIKV replication as well as vaccine and drug development. In this study, various virological assays pertaining to ZIKV are illustrated and discussed.

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Here, the authors present a simple and efficient protocol to define a linear antigenic epitope using a purified monoclonal antibody and peptide scanning through dot-blot hybridization. The identified epitope can then be used in therapeutic and diagnostic applications.

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

This protocol describes the recovery of infectious Zika virus from a two-plasmid infectious cDNA clone.

Rescue and Characterization of Recombinant Virus from a New World Zika Virus Infectious Clone

Current multiplexed diagnostics to detect Zika, chikungunya, and dengue viruses require complex sample preparation and expensive instrumentation, and are difficult to use in low resource environments. We show a diagnostic that uses isothermal amplification with target-specific strand displaceable probes to detect and differentiate these viruses with high sensitivity and specificity.

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

A protocol to evaluate antigen-specific T-cell responses in the immunoprivileged organs of the Ifnar1-/- murine model for the Zika virus (ZIKV) infection is described. This method is pivotal for investigating the cellular mechanisms of the protection and immunopathogenesis of ZIKV vaccines and is also valuable for their efficacy evaluation.

Evaluation of Zika Virus-specific T-cell Responses in Immunoprivileged Organs of Infected Ifnar1-/- Mice

We describe a method to evaluate the effect of pre-existing immunity against dengue virus on the Zika virus infection by using human serum, primary human cells, and infection quantification by quantitative real-time polymerase chain reaction.

Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells

The goal of the protocol is to demonstrate the techniques used to investigate viral disease by isolating and quantifying Zika virus, from multiple organs in a mouse following infection.

Isolation and Quantification of Zika Virus from Multiple Organs in a Mouse

The presented protocol can determine the vector competence of Aedes aegypti mosquito populations for a given virus, such as Zika, in a containment setting.

Vector Competence Analyses on Aedes aegypti Mosquitoes using Zika Virus

In this work, we describe the protocols used in replicon-based and viral enzyme-based assays to screen for inhibitors of Zika virus replication in a high-throughput screening format.

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Multiplex fluorescence immunoassays are becoming a reference for serology testing. Their application, however, is limited by the complexity and time-consuming bead-analyte coupling processes. This report presents a semi-automated, reproducible multiplex microsphere bead coupling protocol that is comparable to the standard method while considerably reducing time to results.

A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses

Discover how to identify Zika virus specific peptides for diagnostic assays using high-density peptide microarrays. This method detects IgM and IgG antibodies to provide clinicians with accurate infection timelines.

Zika Virus Specific Diagnostic Epitope Discovery

Explore More Videos